Clinical Trial Update: A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) [Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 2 study evaluating Zilovertamab Vedotin (MK-2140) in relapsed or refractory diffuse large B-cell lymphoma, current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zilovertamab vedotin (zilovertamab vedotin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING